This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sangamo BioSciences Presents Clinical Data From SB-728-T HIV Study Demonstrating Long-Term Immune Reconstitution And Reduction In The HIV DNA Reservoir In Subjects With Long-Term Infection

RICHMOND, Calif., Nov. 4, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of clinical data from its program to develop a ZFP Therapeutic ® for HIV/AIDS.  The data demonstrate a reduction in the HIV DNA reservoir since receiving SB-728-T in seven of nine HIV-infected subjects on long-term anti-retroviral therapy (ART), despite a median duration of HIV infection of 21 years and baseline CD4 T-cell counts prior to SB-728-T treatment of <500 cells/µl. The data were presented  at a translational medicine meeting organized by The Lancet and Cell publications and entitled, "What Will it Take to Achieve an AIDS-Free World?" which is being held in San Francisco, November 3-5, 2013.

(Logo:  http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

"These data are very promising and demonstrate the important link between SB-728-T treatment and immune reconstitution of central memory and total CD4 T cells and lower HIV DNA levels in subjects at 12 months," said Rafick-Pierre Sekaly, Ph.D., Co-Director & Chief Scientific Officer, The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), who presented the data and whose laboratory carried out the immunologic analyses.

ART successfully suppresses viral load in most subjects, but a significant proportion, so called immunologic non-responders (INR), do not restore normal CD4 counts above 500 cells/µl.  HIV-infected subjects who were classified as INR, enrolled in Sangamo's ongoing SB-728-902 clinical trial (Cohorts 1-3), received a single infusion of SB-728-T which resulted in a durable increase in total CD4 T-cells associated with increases in ZFN-modified CD4 central memory T-cells, specifically memory and stem cell-like cells (TSCM) which provide a long-lasting source of CCR5-modified CD4 T-cells.  Notably, despite the increase in total CD4 T-cells, a long-term decrease in the peripheral blood mononuclear cell (PBMC) HIV reservoir was observed, as measured by proviral DNA using a sensitive assay technique. 

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs